Computational Identification of Novel Kir6 Channel Inhibitors

Xingyu Chen, Arthur Garon, Marcus Wieder, Marien J. C. Houtman, Eva‐Maria Zangerl‐Plessl, Thierry Langer, Marcel A. G. van der Heyden, Anna Stary‐Weinzinger

Abstract

ATP-sensitive potassium ($K_{ATP}$) channels, composed of Kir6.x pore-forming subunits and regulatory sulfonylurea receptor (SUR) subunits, are vital metabolic sensors. Gain-of-function mutations in these subunits lead to Cantú syndrome (CS), a rare multi-systemic disorder for which no specific pharmacotherapy exists. This study describes a computational and experimental pipeline that identified novel Kir6.1 inhibitors. By combining microsecond-scale molecular dynamics (MD) simulations, free energy calculations, and pharmacophore modeling, researchers identified a novel binding site ("Site A") and screened the DrugBank database for repurposable candidates. Three drugs—Travoprost, Betaxolol, and Ritodrine—were validated via patch-clamp electrophysiology as potent inhibitors, even against common Cantú mutations. These findings provide a promising foundation for developing targeted therapies for Cantú syndrome.

Introduction: The Challenge of Cantú Syndrome

Cantú syndrome (CS) is an autosomal dominant disorder characterized by a "gain-of-function" in $K_{ATP}$ channels, primarily due to mutations in the ABCC9 (SUR2) or KCNJ8 (Kir6.1) genes. These mutations cause the channels to remain open more frequently than normal, resulting in clinical features such as hypertrichosis, cardiomegaly, and skeletal abnormalities.

While sulfonylureas like glibenclamide are the standard of care for other $K_{ATP}$-related conditions, they often exhibit reduced efficacy against specific CS-associated mutations. There is a critical need for inhibitors that target the Kir6 pore-forming subunit directly, bypassing the regulatory SUR subunit targeted by traditional drugs.

Computational Pipeline: From Simulation to Screening

The researchers employed a "rational drug design" approach to discover new inhibitory scaffolds. Because a high-resolution structure of Kir6.1 was unavailable at the start of the study, a homology model was constructed using the Kir3.2 channel (PDB: 3SYA) as a template.

To identify potential binding pockets without prior bias, the team performed microsecond-scale MD simulations. They placed 20 molecules of Rosiglitazone—a known Kir6 inhibitor—into a virtual system containing the channel and a lipid bilayer. Over a 1.5 $\mu s$ trajectory, they observed where these molecules naturally partitioned and bound to the protein.

Unbiased MD simulations showing the transition of ligands from the lipid/aqueous phase to the channel protein over 1.5 microseconds.

Following the identification of binding sites, Umbrella Sampling was used to calculate the Potential of Mean Force (PMF), quantifying the binding affinity at each site. The most stable interaction occurred at a location designated as "Site A."

Key Insights: Mapping "Site A"

The simulations pinpointed Site A as a primary inhibitory pocket. Crucially, this site is located in close proximity to the $PIP_2$ binding pocket. Since $PIP_2$ (phosphatidylinositol 4,5-bisphosphate) is the essential lipid activator required to open $K_{ATP}$ channels, drugs binding at Site A likely inhibit the channel by sterically or energetically interfering with $PIP_2$-mediated activation.

Molecular detail of Site A, showing the proximity of the ligand to the PIP2 binding site and key residues such as L57, I60, and V172.

Using the Common Hits Approach (CHA), the team extracted a dynamic pharmacophore—a "chemical blueprint" of the essential interactions at Site A. This model was then used to virtually screen the DrugBank database, searching for approved drugs that matched the required chemical features.

Experimental Validation and Results

The virtual screening identified several "hits," which were then tested using inside-out patch-clamp electrophysiology on HEK293T cells. Three existing medications emerged as potent inhibitors:

  • Travoprost: A prostaglandin analog used for glaucoma, which showed the highest potency ($IC_{50} \approx 2.5 \mu M$).
  • Betaxolol: A selective $\beta_1$ receptor blocker used for hypertension.
  • Ritodrine: A $\beta_2$ adrenoceptor agonist used to stop premature labor.

Importantly, these inhibitors remained effective against the Cantú-associated mutations C166S (in Kir6.2) and S1020P (in SUR2A). This resilience suggests that the identified drugs could be effective for patients who do not respond well to traditional sulfonylureas.

Conclusion and Future Directions

This study successfully integrated high-performance computing with experimental electrophysiology to identify novel $K_{ATP}$ channel inhibitors. By focusing on drug repurposing, the authors have identified candidates that already have established safety profiles, potentially accelerating the path to clinical trials for Cantú syndrome. Future research will focus on confirming the specificity of these drugs for the Kir6.1 isoform and evaluating their efficacy in in vivo animal models of the disease.

Summary updated

Abstract

KATP channels consist of four Kir6.x pore-forming subunits and four regulatory sulfonylurea receptor (SUR) subunits. These channels couple the metabolic state of the cell to membrane excitability and play a key role in physiological processes such as insulin secretion in the pancreas, protection of cardiac muscle during ischemia and hypoxic vasodilation of arterial smooth muscle cells. Abnormal channel function resulting from inherited gain or loss-of-function mutations in either the Kir6.x and/or SUR subunits are associated with severe diseases such as neonatal diabetes, congenital hyperinsulinism, or Cantú syndrome (CS). CS is an ultra-rare genetic autosomal dominant disorder, caused by dominant gain-of-function mutations in SUR2A or Kir6.1 subunits. No specific pharmacotherapeutic treatment options are currently available for CS. Kir6 specific inhibitors could be beneficial for the development of novel drug therapies for CS, particular for mutations, which lack high affinity for sulfonylurea inhibitor glibenclamide. By applying a combination of computational methods including atomistic MD simulations, free energy calculations and pharmacophore modeling, we identified several novel Kir6.1 inhibitors, which might be possible candidates for drug repurposing. The <i>in silico</i> predictions were confirmed using inside/out patch-clamp analysis. Importantly, Cantú mutation C166S in Kir6.2 (equivalent to C176S in Kir6.1) and S1020P in SUR2A, retained high affinity toward the novel inhibitors. Summarizing, the inhibitors identified in this study might provide a starting point toward developing novel therapies for Cantú disease.
BibTeX
@inproceedings{chen2019computational,
  author = {Xingyu Chen and Arthur Garon and Marcus Wieder and Marien J. C. Houtman and Eva‐Maria Zangerl‐Plessl and Thierry Langer and Marcel A. G. van der Heyden and Anna Stary‐Weinzinger},
  title = {{Computational Identification of Novel Kir6 Channel Inhibitors}},
  booktitle = {Frontiers in Pharmacology},
  year = {2019},
  doi = {10.3389/fphar.2019.00549},
}
Figure